420 Lexington Avenue
51 articles with PAVmed
PAVmed Inc. today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3, 2020 at 7:20 a.m. PST / 10:20 a.m. EST.
6/19/2020Biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
PAVmed Inc. to Hold SECOND QUARTER FINANCIAL RESULTS AND BUSINESS UPDATE Conference Call on August 22, 2018
PAVmed Inc. announced that the Company will report second quarter financial results on or before August 14, 2018 and host a conference call on Wednesday, August 22, 2018 at 4:30 p.m. Eastern time.
Medical device veteran joins as company approaches important regulatory and commercial milestones
PAVmed has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market
PAVmed Inc. announced the closing of its oversubscribed equity subscription rights offering (the “Rights Offering”), which raised the maximum gross proceeds of $10,350,000.
Equity subscription rights offering expired at 5:00 p.m. Eastern Time on Thursday, June 7, 2018 and, as such, the rights are no longer exercisable
Each right now entitles the holder to purchase one unit at the subscription price of $1.15 per unit and each unit remains comprised of one share of the Company’s common stock and one Series Z Warrant.
Company had filed a preliminary prospectus as part of a registration statement on Form S-1 with the Securities and Exchange Commission for a rights offering to stockholders of record on Monday, May 21, 2018.
Conference call to be held May 30, 2018 at 4:30 p.m. Eastern time
The effective date of the exercise price reduction will be June 1, 2018.
PAVmed and Case Western Reserve University Finalize Definitive Licensing Agreement for Groundbreaking EsoCheck Technology
PAVmed subsidiary Lucid Diagnostics Inc. secures exclusive worldwide license for EsoCheck
PAVmed Signs Letter of Intent with Case Western Reserve University to Commercialize Groundbreaking EsoCheck Technology
Five-minute, office-based alternative to endoscopy utilizes highly accurate DNA biomarkers to detect Barrett’s Esophagus, the precursor to a common highly lethal form of esophageal cancer
Conference call begins at 4:30 p.m. Eastern time today
The Offer expired at 5:00 p.m. Eastern time on April 2, 2018.
PAVmed today announced it intends to file exchange offer materials (the “Exchange”) providing the holders of the Company’s outstanding Series W Warrants (Nasdaq: PAVMW, the “W Warrant”) with the opportunity to exchange 2 W Warrants for 1 Series Z Warrant (the “Z Warrant”).
PAVmed today announced the completion of its previously announced offer to exercise its publicly-traded warrants (the “Series W Warrants”) at a temporarily reduced exercise price of $2.00 per share.
PAVmed Announces Closing of Over-Allotment Option with Respect to Firm Commitment Common Stock Offering
The Firm Shares and the Option Shares were sold at a public offering price of $1.80 per share.
PAVmed announced underwritten public offering of 2,415,278 shares of its common stock at a public offering price of $1.80 per share.
PAVmed announced the pricing of its previously announced underwritten public offering of 2,415,278 shares of its common stock at a price to the public of $1.80 per share. In addition,